Christian Squillante, MD
Hematology & Oncology · Voorhees, NJNPI 1720212467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,500 of the $1,820 with a category attached, or 82.4%. Roche Molecular Systems, Inc. accounts for 82.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,515 and has fallen 92.3% since, to $117 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 19 payments — averaging $95.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Molecular Systems, Inc.$2K
- Pfizer$85
- Eisai Inc.$53
- Bayer$32
- Novartis$31
- Daiichi Sankyo Inc.$28
- plus $92 from 5 others
Across 71 payments — averaging $12,351 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$440K
- AstraZeneca$242K
- Merck$164K
- Astrazeneca UK Limited$30K
- Bayer$500
What the payments were for
- Speaking & faculty fees$1,50082%
- Food & beverage$29516%
- Education$251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Molecular Systems, Inc. | 1 | $1,500 |
| Pfizer | 5 | $85 |
| Eisai Inc. | 3 | $53 |
| Bayer | 2 | $32 |
| Novartis | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Convatec Inc. | 1 | $26 |
| Merck | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Seagen Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,820 in reported general payments places this provider in the 40th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 127 | $1,707,895 |
| XtandiEnzalutamide | 85 | $1,152,189 |
| Abiraterone Acetate | 375 | $1,126,055 |
| CabometyxCabozantinib S-Malate | 26 | $683,980 |
| ErleadaApalutamide | 28 | $394,025 |
| InlytaAxitinib | 16 | $371,326 |
| LenvimaLenvatinib Mesylate | 14 | $337,923 |
| ZytigaAbiraterone Acetate | 13 | $142,477 |
| EliquisApixaban | 22 | $11,932 |
| Ondansetron OdtOndansetron | 140 | $1,369 |
| Prednisone | 341 | $1,053 |
| Prochlorperazine Maleate | 117 | $1,011 |
| Bicalutamide | 45 | $718 |
| Dexamethasone | 104 | $555 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $32 | $1,707,895127 claims |
| PfizerInlyta, Eliquis | $85 | $383,25838 claims |
| Eisai Inc.Lenvima | $53 | $337,92314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Voorhees
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.